Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | RO7227166 |
| Trade Name | |
| Synonyms | RO 7227166|RO-7227166|Ensomafusp Alfa|RG6076|RG-6076|RG 6076|Englumafusp Alfa |
| Drug Descriptions |
RO7227166 is a bispecific antibody that targets both CD19 and TNFRSF9 (4-1BB), potentially resulting in enhanced anti-tumor immune response (Blood (2022) 140 (Supplement 1): 9461-9463). |
| DrugClasses | CD19 Antibody 21 TNFRSF9 Antibody 36 |
| CAS Registry Number | NA |
| NCIT ID | C169052 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Glofitamab-gxbm + Obinutuzumab + RO7227166 + Tocilizumab | Glofitamab-gxbm Obinutuzumab RO7227166 Tocilizumab | 0 | 1 |
| Glofitamab-gxbm + RO7227166 | Glofitamab-gxbm RO7227166 | 0 | 0 |
| Obinutuzumab + RO7227166 + Tocilizumab | Obinutuzumab RO7227166 Tocilizumab | 0 | 1 |
| RO7227166 | RO7227166 | 0 | 0 |